Health News

VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED).

Read more

Filed under: Pharmacy News
Tags: Drug, male, Pharmacy

Related posts

• Vigor-25 contains hidden drug ingredient, warns FDA (0)
  The U.S. Food and Drug Administration says Vigor-25, a product marketed as a natural dietary supplement to enhance male sexual performance, should not be purchased or used because it contains sildenafil, the active ingredient in the prescription drug Viagra. Read more [tags] Pharmacy News [/tags]
  
  
• Vantia Therapeutics’ Lead Candidate VA106483 Enters Phase IIb Trial For Nocturia (0)
  Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the [...]
  
  
• Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court (0)
  Baum Hedlund announces that Taiwanese hemophiliacs infected by HIV-contaminated medications have petitioned the United States Supreme Court to allow their claims to proceed in California. Their suits contend that California-based defendants illegally used paid plasma donors at high risk for transmitting blood-borne diseases (i.v. drug users, prisoners, and promiscuous urban gay males) to make injected [...]
  
  
• Scientists at retrovirus conference present findings on microbicide gel, Truvada, male circumcision, ART care by nurses (0)
  At the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on Monday, researchers "suggested the potential" of a gel containing the antiretroviral drug tenofovir to reduce the risk of anal HIV transmission, TIME's "Healthland" blog reports. Read more [tags] Pharmacy News [/tags]
  
  
• S1 Biopharma announces foray into male sexual health with S1P-205 (0)
  S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD. Read more [tags] Pharmacy News [/tags]